Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

NIH awards $1.2 million EUREKA grant to study protein misfolding

Three University of Massachusetts Amherst scientists have received a four-year, $1.2 million EUREKA grant from the U.S. National Institutes of Health (NIH) to study folding and misfolding of secretory proteins in the cell's protein factory, the endoplasmic reticulum, where misfolding can lead to diseases such as cystic fibrosis and liver cirrhosis.

3 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.

31 Aug 2010

Toshiba announces 1,000th worldwide MR installation

Diagnostic imaging leader Toshiba America Medical Systems, Inc. has installed its 1,000th MR system worldwide. Kosair Children's Medical Center - Brownsboro, the only pediatric outpatient facility of its type in Kentucky, is the site of Toshiba's milestone installation. The new facility, dedicated to the care of children, is located in the eastern suburbs of Louisville, Ky., and is the newest addition to Kosair Children's Hospital and the Norton Healthcare Network.

30 Aug 2010

PFF announces $400,000 grant for pulmonary fibrosis research

The Pulmonary Fibrosis Foundation today announced that, in partnership with the American Thoracic Society (ATS) and Coalition for Pulmonary Fibrosis (CPF), $400,000 in new pulmonary fibrosis research grants as part of the 2010 ATS Partner Award Program for Pulmonary Fibrosis Research.

30 Aug 2010

Luminex launches FDA-cleared xTAG Cystic Fibrosis 60 Kit v2 diagnostic test

Luminex Corporation, the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

From Thermo Fisher Scientific Inc. 27 Aug 2010

FibroGen announces study results of recombinant human type III collagen in corneal damage

FibroGen, Inc., today announced results of a 2-year clinical study demonstrating that surgical implantation of biosynthetic corneas formulated with the company's proprietary recombinant human type III collagen (rhCIII) restored vision and promoted nerve regeneration (restoring sensitivity) in patients who had corneal damage and significant vision loss.

26 Aug 2010

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

Vitamin D may be an effective therapy to treat and even prevent allergy to a common mold that can cause severe complications for patients with cystic fibrosis and asthma.

26 Aug 2010

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.

26 Aug 2010

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen's Homspera.

25 Aug 2010

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.

25 Aug 2010

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

The Coalition for Pulmonary Fibrosis (CPF) and the American Thoracic Society (ATS), the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced that the CPF will again partner with the ATS to continue to fund Pulmonary Fibrosis (PF) research.

24 Aug 2010

Pulmonary Fibrosis Foundation to support 2010 National PF Week

The Pulmonary Fibrosis Foundation (PFF) today expressed its support for the 2010 National Pulmonary Fibrosis Awareness Week activities, to be held from September 11-18, 2010 in Washington D.C.

20 Aug 2010

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Researchers at Massachusetts General Hospital found that patients with nonalcoholic fatty liver disease (NAFLD) who carry an allele of the PNPLA3 gene have an increased risk of developing advanced disease, including nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. A second study supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) validates these findings and further concludes that in pediatric patients, the same allele is associated with earlier disease presentation.

18 Aug 2010

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis. Full details of the study appear in the September issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

18 Aug 2010

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

Cryo-Cell International, Inc., one of the largest and most established leaders in stem cell innovation, today announced a research and development collaboration agreement with Monash University in Australia. The partnership will allow scientists from the University's Centre of Inflammatory Diseases to conduct pre-clinical studies using Cryo-Cell's proprietary C'elle menstrual stem cell technology (MenScs) to identify potential future therapies to treat autoimmune diseases such as multiple sclerosis.

18 Aug 2010

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

17 Aug 2010

Research confirms genetic link to advanced fatty liver disease

17 Aug 2010

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

13 Aug 2010

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

In a move likely to secure its place as a leading provider of medical radiation countermeasures, Humanetics Corporation today announced that it has secured exclusive worldwide licenses to two new treatments that provide short and long-term post-exposure protection from ionizing radiation acquired during a terrorist act, nuclear or radiological attack or accident, as part of cancer radiotherapy or even during routine diagnostic CT scans.

13 Aug 2010

Fibrosis News and Research

Further Reading

NIH awards $1.2 million EUREKA grant to study protein misfolding

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

Toshiba announces 1,000th worldwide MR installation

PFF announces $400,000 grant for pulmonary fibrosis research

Luminex launches FDA-cleared xTAG Cystic Fibrosis 60 Kit v2 diagnostic test

FibroGen announces study results of recombinant human type III collagen in corneal damage

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

Pulmonary Fibrosis Foundation to support 2010 National PF Week

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Research confirms genetic link to advanced fatty liver disease

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News